Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

Medicine, Oncology, Pharmacology +8

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint et al. · Clinica Chimica Acta · 2011 · 172 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +12

Clearance calculations in hemodialysis: Application to blood, plasma, and dialysate measurements for ethambutol

Ching S. Lee, Thomas Marbury, Leslie Z. Benet · Journal of Pharmacokinetics and Biopharmaceutics · 1980 · 57 citations

Pharmacy, Nephrology, Pharmacokinetics +14

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

Ying Chen, Brian I. Rini, Robert J. Motzer et al. · Targeted Oncology · 2015 · 20 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Sequential molecularly targeted drug therapy including axitinib for a patient with end‐stage renal failure and metastatic renal cell carcinoma

Hayato Nishida, Hiroki Fukuhara, Atsushi Yamagishi et al. · Hemodialysis International · 2015 · 12 citations

Medicine, Nephrology, Oncology +17